Background: Hyla (“Henry”) Bristow Stallard (1901–1973) was an English ophthalmologist who made a significant contribution to ophthalmology and to ocular oncology. Summary: Stallard achieved international fame as an athlete during his early years, breaking several records and winning a medal in the 1924 Paris Olympic Games. He served as Consultant Surgeon and Pathologist at Moorfields and St. Bartholomew’s Hospitals. During his training, he wrote a thesis entitled “Radiant Energy as (a) a pathogenic and (b) a therapeutic agent in ophthalmic disorders”, for which he was awarded the Gifford Edmonds Prize Essay in 1932. In 1946, he published his influential textbook on eye surgery, which ran to six editions. In the introduction to this book, he highlighted the requirements of a good surgeon, which are as valid today as they were in his time. He published numerous scientific articles and delivered many eponymous lectures in several countries, receiving a large number of prestigious awards. In 1972, he was elected President of the Ophthalmological Society of the UK. One of Stallard’s great achievements was the development of plaque brachytherapy for choroidal melanomas, which involved designing the applicator, determining the required radiation dosimetry, and publishing long-term outcome studies. This was at a time when these tumours were widely considered to be untreatable with radiotherapy because they are so radio-resistant. He also pioneered iris melanoma brachytherapy, trans-retinal and trans-scleral tumour biopsy, partial choroidectomy, iridocyclectomy, and iridectomy, orbital surgery, retinoblastoma treatment, and he invented or designed several instruments. Key Messages: Stallard’s legacy extends beyond specific therapeutic techniques by inspiring ophthalmologists to teach, perform research, and publish their findings and innovations for the benefit of future patients around the world. This review focuses on Stallard’s contribution to the treatment of uveal melanoma.

Hyla (“Henry”) Bristow Stallard (1901–1973) was an English ophthalmologist who made a significant contribution to ophthalmology and to ocular oncology. He achieved international fame as an athlete during his early years, breaking several records and winning a medal in the 1924 Paris Olympic Games. He served as Consultant Surgeon and Pathologist at Moorfields and St. Bartholomew’s Hospitals. In 1946, he published his influential textbook on eye surgery, which ran to six editions. In the introduction to this book, he highlighted the requirements of a good surgeon, which are as valid today as they were in his time. He published numerous scientific articles and delivered many eponymous lectures in several countries, receiving a large number of prestigious awards. In 1972, he was elected President of the Ophthalmological Society of the UK. One of Stallard’s great achievements was the development of radiotherapy for intraocular melanomas, which involved designing the applicator, determining the required radiation dosimetry, and publishing long-term outcome studies. This was at a time when these tumours were widely considered to be untreatable with radiotherapy because they are so radio-resistant. He also pioneered other treatments for intraocular tumours and he invented or designed several instruments. His legacy extends beyond specific therapeutic techniques by inspiring ophthalmologists to teach, perform research, and publish their findings and innovations for the benefit of future patients around the world. This review focuses on Stallard’s contribution to the treatment of uveal melanoma.

1.
Stallard
HB
.
Eye surgery
.
Bristol
:
John Wright and Sons, Ltd.
;
1946
.
2.
Stallard
HB
.
The presidential address. The evolution of lateral orbitotomy
.
Trans Ophthalmol Soc UK
.
1973
;
93
(
0
):
3
17
.
3.
Stallard
HB
.
Radiotherapy of malignant intra-ocular neoplasms
.
Br J Ophthalmol
.
1948
;
32
(
9
):
618
39
.
4.
Moore
RF
,
Stallard
HB
,
Milner
JG
.
Retinal gliomata treated by radon seeds
.
Br J Ophthalmol
.
1931
;
15
(
12
):
673
96
.
5.
Moore
RF
.
Choroidal sarcoma treated by the intraocular insertion of radon seeds
.
Br J Ophthalmol
.
1930
;
14
(
4
):
145
52
.
6.
Stallard
HB
.
Comparative value of radium and deep x rays in the treatment of retinoblastoma
.
Br J Ophthalmol
.
1952
;
36
(
6
):
313
24
.
7.
Stallard
HB
.
Radiotherapy for malignant melanoma of the choroid
.
Br J Ophthalmol
.
1966
;
50
(
3
):
147
55
.
8.
Zemba
M
,
Dumitrescu
OM
,
Gheorghe
AG
,
Radu
M
,
Ionescu
MA
,
Vatafu
A
, et al
.
Ocular complications of radiotherapy in uveal melanoma
.
Cancers
.
2023
;
15
(
2
):
333
.
9.
Damato
B
.
Vasculopathy after treatment of choroidal melanoma
. In:
Joussen
A
,
Gardner
TW
,
Kirchhof
B
,
Ryan
SJ
, editors.
Retinal vascular disease
.
Berlin
:
Springer
;
2007
. p.
582
91
.
10.
Mantel
I
,
Schalenbourg
A
,
Bergin
C
,
Petrovic
A
,
Weber
DC
,
Zografos
L
.
Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma
.
Am J Ophthalmol
.
2014
;
158
(
4
):
693
701 e2
.
11.
Fallico
M
,
Chronopoulos
A
,
Schutz
JS
,
Reibaldi
M
.
Treatment of radiation maculopathy and radiation-induced macular edema: a systematic review
.
Surv Ophthalmol
.
2021
;
66
(
3
):
441
60
.
12.
Stallard
HB
.
Radiant energy as (a) a pathogenic and(b) a therapeutic agent in ophthalmic disorders
.
Br J Ophthalmol
.
1933
;
17
(
5
):
294
7
.
13.
Damato
B
,
Kacperek
A
,
Chopra
M
,
Sheen
MA
,
Campbell
IR
,
Errington
RD
.
Proton beam radiotherapy of iris melanoma
.
Int J Radiat Oncol Biol Phys
.
2005
;
63
(
1
):
109
15
.
14.
Tsimpida
M
,
Hungerford
J
,
Arora
A
,
Cohen
V
.
Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma
.
Eye
.
2011
;
25
(
12
):
1607
11
.
15.
Hussain
RN
,
Damato
B
,
Heimann
H
.
Choroidal biopsies; a review and optimised approach
.
Eye
.
2023
;
37
(
5
):
900
6
.
16.
Damato
B
,
Eleuteri
A
,
Taktak
AF
,
Coupland
SE
.
Estimating prognosis for survival after treatment of choroidal melanoma
.
Prog Retin Eye Res
.
2011
;
30
(
5
):
285
95
.
17.
Cunha Rola
A
,
Taktak
A
,
Eleuteri
A
,
Kalirai
H
,
Heimann
H
,
Hussain
R
, et al
.
Multicenter external validation of the Liverpool Uveal Melanoma Prognosticator Online: an OOG collaborative study
.
Cancers
.
2020
;
12
(
2
):
477
.
18.
Stallard
HB
.
Partial choroidectomy
.
Br J Ophthalmol
.
1966
;
50
(
11
):
660
2
.
19.
Damato
B
.
Surgical resection of choroidal melanoma
. In:
Schachat
A
, editor.
Ryan’s retina
.
London
:
Elsevier
;
2022
.
20.
Chang
M
,
Dalvin
LA
,
Mazloumi
M
,
Martin
A
,
Yaghy
A
,
Yang
X
, et al
.
Prophylactic intravitreal bevacizumab after plaque radiotherapy for uveal melanoma: analysis of visual acuity, tumor response, and radiation complications in 1131 eyes based on patient age
.
Asia Pac J Ophthalmol
.
2020
;
9
(
1
):
29
38
.
21.
Hiong
A
,
O'Day
R
,
Fog
LS
,
McKay
D
,
McKenzie
J
,
Ameratunga
M
, et al
.
Globe salvage and vision preservation by neoadjuvant darovasertib and crizotinib in uveal melanoma
.
Ophthalmol Retina
.
2024
;
8
(
4
):
325
30
.
22.
Stallard
HB
.
Surgery of malignant melanoma of the iris
.
Br J Ophthalmol
.
1951
;
35
(
12
):
774
83
.
23.
Stallard
HB
.
Partial cyclectomy
.
Br J Ophthalmol
.
1961
;
45
(
12
):
797
802
.
24.
Stallard
HB
.
Partial cyclectomy. Some further modifications in techique
.
Br J Ophthalmol
.
1964
;
48
:
1
6
.
25.
Rospond-Kubiak
I
,
Damato
B
.
The surgical approach to the management of anterior uveal melanomas
.
Eye
.
2014
;
28
(
6
):
741
7
.
You do not currently have access to this content.